Jatenzo for Male Hypogonadism: Dosing, Evidence, and Clinical Guidance

What Is Jatenzo and How Does It Work?

Jatenzo is an oral softgel capsule containing testosterone undecanoate, a fatty-acid ester of testosterone that is absorbed through the intestinal lymphatic system rather than the portal circulation. Because lymphatic transport bypasses the liver, the first-pass hepatic degradation that historically made oral testosterone ineffective is avoided. Once testosterone undecanoate enters the thoracic duct and systemic circulation, pancreatic lipases cleave the undecanoate side chain and release free testosterone [1].

This absorption mechanism depends directly on dietary fat. A meal containing approximately 15 to 20 g of fat raises peak testosterone exposure by roughly 2.5-fold compared with fasting conditions, which is why Jatenzo must always be taken with food [1]. The FDA label specifies that patients who cannot tolerate fatty meals should use an alternative testosterone formulation [2].

Testosterone undecanoate itself has been available in injectable form (Aveed) since 2014, but the oral version (Jatenzo) received FDA approval in March 2019, making it the first oral testosterone product approved in the United States in decades [2]. Earlier oral methyltestosterone products carried hepatotoxicity concerns because they used a different metabolic route; Jatenzo's lymphatic pathway does not carry the same liver toxicity signal [3].

The half-life of oral testosterone undecanoate after Jatenzo is approximately 3 to 5 hours, meaning twice-daily dosing is required to maintain stable serum concentrations across the day [1]. Levels peak (T-max) roughly 1 to 4 hours post-dose depending on meal composition [1].

Who Qualifies for Jatenzo? Diagnosing Male Hypogonadism

Male hypogonadism is defined by persistently low testosterone combined with clinical symptoms. The Endocrine Society 2018 Clinical Practice Guideline recommends confirming a total testosterone below 300 ng/dL on at least two separate morning (pre-10:00 AM) fasting measurements before initiating treatment [4]. The CDC-harmonized reference cutoff used in some laboratory reporting systems is 264 ng/dL, which can create confusion during interpretation [5].

Symptoms must accompany the biochemical finding. Common presentations include reduced libido, fatigue, depressed mood, decreased lean mass, increased adiposity, and impaired erection quality [4]. The Endocrine Society guideline states: "We recommend making the diagnosis only in men with symptoms and signs consistent with testosterone deficiency and unequivocally low serum testosterone concentrations." [4]

Before attributing low testosterone to primary testicular failure or hypothalamic-pituitary disease, clinicians should rule out reversible contributors. Obesity, obstructive sleep apnea, opioid use, glucocorticoid therapy, and acute illness all suppress the hypothalamic-pituitary-gonadal axis and can produce transiently low values [4]. Free testosterone measurement adds diagnostic value when sex-hormone-binding globulin is expected to be abnormal, such as in men with cirrhosis, hyperthyroidism, or morbid obesity [4].

Jatenzo's FDA-approved indication covers two etiologic categories: primary hypogonadism (testicular failure, e.g., bilateral orchiectomy, Klinefelter syndrome, cryptorchidism, radiation) and hypogonadotropic hypogonadism (pituitary or hypothalamic disease, e.g., idiopathic hypogonadotropic hypogonadism, Kallmann syndrome, panhypopituitarism) [2]. It is not approved for age-related testosterone decline absent confirmed pathology, nor for use in women [2].

Key Clinical Trial Evidence: Swerdloff et al. 2020

The primary evidence base for Jatenzo in male hypogonadism is the open-label Phase 3 trial published by Swerdloff and colleagues in the Journal of Clinical Endocrinology and Metabolism (2020) [6]. The study enrolled 166 hypogonadal men (total testosterone <300 ng/dL at screening) at multiple US centers. Participants started at 237 mg twice daily and were dose-adjusted at Day 21, 28 based on a 4-hour post-morning-dose serum testosterone [6].

The primary efficacy endpoint was the percentage of patients achieving average serum testosterone within the normal range (300, 1 to 000 ng/dL) over 24 hours on Day 90. Eighty-seven percent of patients met this endpoint [6]. Secondary endpoints confirmed improvements in sexual function scores, fatigue scales, and body composition over the 120-day treatment period [6].

Pharmacokinetic data from the trial showed that the mean (SD) C-avg over 24 hours on Day 90 was 456 (200) ng/dL among patients who dose-titrated appropriately [6]. The highest tertile of patients had C-avg values near the upper boundary of normal, which underscores why ongoing monitoring and dose adjustment are essential rather than optional [6].

A separate pharmacokinetic substudy confirmed that Jatenzo administered with a standardized meal containing roughly 400 calories (15 g fat) maintained therapeutic levels across both doses in the series, supporting the real-world meal-timing flexibility of the regimen [1].

The American Urological Association (AUA) 2018 testosterone deficiency guidelines cite oral testosterone undecanoate as a viable route of administration when patients prefer to avoid injections or transdermal preparations, though the guidelines note that twice-daily adherence and the food requirement add behavioral complexity compared with weekly injections [7].

Jatenzo Dosing Protocol for Male Hypogonadism

Starting dose is 237 mg (one 237 mg softgel) taken orally twice daily, approximately 6 to 8 hours apart, each dose with a meal [2]. This applies to all adult men regardless of body weight at initiation, because inter-individual pharmacokinetic variability is high enough that weight-based dosing has not been validated for this formulation [6].

Dose adjustment occurs at the Day 21, 28 visit using a serum testosterone drawn 4 hours after the morning dose (approximating C-max). The prescribing algorithm from the FDA label is:

• If T is above 1 to 050 ng/dL, decrease to 158 mg twice daily [2].
• If T is 300, 1 to 050 ng/dL, continue current dose [2].
• If T is below 300 ng/dL, increase to 396 mg twice daily (two 198 mg softgels) [2].

Subsequent adjustments follow the same algorithm at each monitoring visit. The available dose strengths are 158 mg, 198 mg, and 237 mg softgels, allowing a practical range of 316 mg/day (2 x 158 mg) to 474 mg/day (2 x 237 mg) [2]. Doses above 396 mg twice daily have not been studied and are not recommended [2].

Patients who miss a dose should take the next dose with their next meal and not double up [2]. Because the half-life is short (approximately 3 to 5 hours), a missed dose can result in a several-hour window of subtherapeutic testosterone, which may be clinically noticeable in men with highly symptomatic disease [1].

Blood Pressure: The Boxed Warning Clinicians Cannot Ignore

Jatenzo carries an FDA boxed warning for blood pressure elevation. In the Swerdloff 2020 trial, mean systolic blood pressure increased by approximately 3 to 5 mmHg from baseline, and 21% of participants required initiation or dose escalation of antihypertensive medication during the study [6]. Diastolic increases were smaller but consistent [6].

The mechanism is likely sodium and water retention driven by androgen receptor activation in the renal tubule, an effect shared by all testosterone replacement modalities but potentially amplified by the higher peak serum levels achievable with an oral formulation taken with fat-rich meals [8]. The cardiovascular risk implications of a 3 to 5 mmHg systolic increase are not trivial: a meta-analysis of 61 prospective studies (N = 1 million) found that each 2 mmHg rise in systolic blood pressure is associated with a 7% increase in ischemic heart disease mortality [9].

The FDA label states that Jatenzo is contraindicated in men with a history of serious cardiovascular events within 6 months, including myocardial infarction, stroke, or acute coronary syndrome, and in men with uncontrolled hypertension (blood pressure consistently above 160/100 mmHg despite medication) [2]. Clinicians should measure blood pressure before prescribing, at the Day 21, 28 titration visit, and at every subsequent monitoring visit [2]. If blood pressure exceeds 130/80 mmHg on two consecutive readings, lifestyle modification and antihypertensive therapy should be addressed before continuing treatment [2].

For the broader cardiovascular picture in testosterone-treated men, the TRAVERSE trial (N = 5,204, NEJM 2023) found that testosterone therapy in men with hypogonadism and high cardiovascular risk did not produce a significant increase in MACE over a mean 33 months of follow-up compared with placebo, though the trial used topical testosterone gel rather than oral testosterone undecanoate [10]. Whether TRAVERSE data fully applies to Jatenzo's pharmacokinetic profile, with its higher peak-to-trough ratio, is an open question clinicians should discuss with patients.

Monitoring Schedule After Starting Jatenzo

Consistent laboratory and clinical follow-up is not optional with Jatenzo. The recommended monitoring schedule based on the FDA label and Endocrine Society guideline is:

Before starting: Total testosterone (two morning samples), LH, FSH, complete blood count (CBC), hematocrit, PSA (men over 40), blood pressure, and hepatic function panel [2][4].

Day 21, 28: Serum testosterone 4 hours after morning dose for dose adjustment; blood pressure; symptom review [2].

Month 3 (Day 90): Serum testosterone 4-hour post-morning dose; hematocrit; blood pressure; lipid panel; PSA if applicable [2][4].

Every 3 to 6 months ongoing: Serum testosterone; hematocrit; blood pressure; symptom review. PSA and DRE annually in men over 40 or as clinically indicated [4].

Hematocrit elevation (polycythemia) is a well-documented effect of testosterone therapy across all formulations. The Endocrine Society guideline recommends holding or reducing testosterone if hematocrit exceeds 54%, given thrombotic risk [4]. In the Swerdloff trial, hematocrit increases were modest (mean 1, 2 percentage points) but individual outliers reached values requiring dose reduction [6].

Lipid changes with Jatenzo are modest. Mean HDL decreased by approximately 3 mg/dL in the key trial [6]. Clinicians should obtain a fasting lipid panel at baseline and at 3 months, then annually thereafter [4].

Comparing Jatenzo to Other Testosterone Formulations

Male hypogonadism can be treated with intramuscular injections (testosterone cypionate or enanthate), subcutaneous injections (testosterone cypionate), transdermal gels or patches, buccal tablets, subcutaneous pellets, or Aveed (injectable testosterone undecanoate) [4]. Each has distinct pharmacokinetic profiles, adherence demands, and side-effect considerations.

Jatenzo offers needle-free dosing and avoids skin-to-skin transfer risk associated with transdermal gels, a concern in households with female partners or children [2]. The twice-daily schedule with food is its primary adherence challenge; a patient who regularly skips breakfast or eats very low-fat meals will have erratic absorption [1].

Testosterone cypionate 200 mg IM every 2 weeks (or 100 mg weekly) produces well-characterized pharmacokinetics at substantially lower cost. A 10 mL multi-dose vial of testosterone cypionate costs approximately $30, 60 at most US pharmacies, while Jatenzo's list price exceeded $700 per month at launch [11]. Insurance coverage for Jatenzo varies; prior authorization is frequently required, and many plans mandate failure of at least one lower-cost formulation first [2].

Transdermal testosterone 1.62% gel (AndroGel) has the largest post-marketing safety database, with data from the TOM trial (N = 209) and TRAVERSE trial (N = 5,204) providing cardiovascular safety context that Jatenzo-specific oral data cannot yet match [10][12]. Oral formulations have a theoretical advantage in reversibility, since stopping the twice-daily pill restores near-baseline serum levels within 24 hours due to the short half-life [1].

Drug Interactions and Contraindications

Testosterone is a substrate and moderate inducer of CYP3A4. Jatenzo has several clinically relevant interactions [2]:

Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) may increase testosterone exposure and push levels above range. Dose reduction or increased monitoring frequency is warranted [2].

Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin) may decrease testosterone exposure, potentially rendering therapy ineffective without dose escalation [2].

Insulin and oral hypoglycemics: Testosterone improves insulin sensitivity. Men with diabetes starting Jatenzo may need downward adjustment of insulin or secretagogue doses to prevent hypoglycemia [2][4].

Warfarin: Androgens potentiate anticoagulant effects, increasing INR. Monthly INR monitoring is recommended after any testosterone dose change in men on warfarin [2].

Corticosteroids: Concurrent use may increase fluid retention and blood pressure, compounding Jatenzo's own blood pressure risk [2].

Absolute contraindications include known or suspected breast carcinoma, known or suspected prostate carcinoma, uncontrolled hypertension, and pregnancy (Jatenzo is not approved in women) [2]. A baseline PSA above 4 ng/mL or a palpable prostate nodule requires urology evaluation before testosterone can be initiated, per Endocrine Society guidance [4].

Patient Counseling Points

Several counseling points are specific to Jatenzo and differ from injectable or topical testosterone:

Take every dose with food. The most common cause of inadequate testosterone levels on Jatenzo is taking capsules without a meal, particularly a fat-containing meal. A patient should not take Jatenzo with only black coffee [1].

Twice-daily schedule. Doses taken more than 10 to 12 hours apart may produce a symptomatic trough. Patients should set two daily alarms aligned with meals [2].

Monitor blood pressure at home. Given the boxed warning, a home blood pressure log between clinic visits allows for earlier detection of hypertensive trends. A reading above 140/90 mmHg on two home readings should prompt contact with the prescribing provider before the next scheduled visit [2][4].

Symptom onset timing. Libido and energy improvements are typically noticeable within 3 to 6 weeks. Body composition changes (lean mass gain, fat reduction) require 3 to 6 months of consistent therapy [13]. Patients expecting immediate physical transformation are likely to be disappointed in the first month.

Hematocrit and donation. Men on testosterone should not donate blood without disclosing their treatment, as testosterone use disqualifies donation under American Red Cross guidelines. A hematocrit above 50% at any monitoring visit warrants prompt discussion [4].

What to Expect in the First 90 Days on Jatenzo

Days 1, 7 typically see minimal symptomatic change. Serum testosterone rises into range within 24 to 48 hours of the first dose if taken correctly with food, but the subjective benefits lag because symptom recovery involves receptor upregulation and downstream hormonal changes [13].

Weeks 2, 4 often bring improvements in sleep quality, morning erections, and mood before libido and energy fully normalize. Patients with baseline depression may notice a modest lift; however, Jatenzo is not indicated for depression in the absence of confirmed hypogonadism, and a PHQ-9 baseline score is useful for objective tracking [4].

The Day 21, 28 lab visit is the most consequential early checkpoint. If the 4-hour post-dose testosterone is below 300 ng/dL despite correct dosing with food, dose escalation to 396 mg twice daily is indicated [2]. If the value exceeds 1 to 050 ng/dL, reduction to 316 mg twice daily protects against polycythemia and blood pressure risk [2].

By 90 days, 87% of patients who dose-adjusted appropriately reached the therapeutic range in the Swerdloff trial, and symptom improvement scores (ADAM questionnaire) showed statistically significant improvement from baseline (P<0.001) [6]. Patients who have not responded symptomatically by 3 months despite confirmed in-range testosterone should be evaluated for other contributors to their symptom burden, including thyroid dysfunction, anemia, or sleep apnea [4].

Jatenzo in Men with Obesity and Metabolic Syndrome

Obesity suppresses total testosterone through several mechanisms: aromatase activity in adipose tissue converts testosterone to estradiol, SHBG is reduced (lowering total but not necessarily free testosterone), and leptin resistance impairs hypothalamic GnRH pulsatility [14]. Men with a BMI above 35 kg/m² often present with total testosterone below 300 ng/dL but free testosterone in the low-normal range, complicating the diagnosis [14].

In men with confirmed hypogonadism and obesity, testosterone therapy modestly reduces fat mass and increases lean mass over 12 to 24 months, with effect sizes smaller than those seen with GLP-1 receptor agonists or structured exercise [13]. The combination of testosterone therapy and weight loss intervention shows additive effects on body composition in several small trials [13][14].

For Jatenzo specifically, the food requirement creates a practical advantage in metabolic syndrome patients: the twice-daily meal anchoring may support structured eating patterns. The lymphatic absorption mechanism means that higher dietary fat intake, common in obese populations, does not unpredictably raise testosterone beyond the therapeutic ceiling provided dose titration occurs at Day 21, 28 [1][6].

Blood pressure management in obese hypogonadal men on Jatenzo requires particular attention, since baseline hypertension prevalence is elevated in this population before testosterone is introduced [8][9].